Status:
TERMINATED
Efficacy of LCQ908 on Cardiovascular Risk
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Coronary Artery Disease
Hypertriglyceridemia
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
Brief Summary
This is a study designed to evaluate the potential for the pradigastat (LCQ908) to impact cardiovascular risk.
Detailed Description
This study had 2 parts. Part A was a multicenter, double-blind, randomized, placebo-controlled, non-confirmatory crossover study assessing response to a high-fat meal challenge in the setting of pradi...
Eligibility Criteria
Inclusion
- History of coronary artery disease
- Elevated triglycerides
- On medication to help lower cholesterol
Exclusion
- Poorly controlled diabetic patients and/or change in diabetic medication within 12 weeks of screening
- History of myocardial infarction (heart attack) within 6 months of screening
- History of a procedure to open a blocked coronary artery within 12 months of enrollment
- History of Coronary Artery Bypass Graft (CABG) surgery
- History of congestive heart failure
- History of significant heart valve disease
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT01474434
Start Date
December 1 2011
End Date
June 1 2014
Last Update
April 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Pasadena, California, United States, 91105